
Zenith Drugs (NSE SME)
Feb 19, 2024 - Feb 22, 2024
Price | ₹75 - ₹79 |
Premium | ₹35 |
---|---|
Lot size | 1600 |
Allotment | Feb 23, 2024 |
Listing | Feb 27, 2024 |
Category | Lot(s) | Qty | Amount | Reserved |
---|---|---|---|---|
Retail | 1 | 1600 | 126400 | 940 |
HNI | 2 | 3200 | 252800 | 403 |
Last updated on 22-Feb-2024 17:00:03
Category | Offered | Applied | Times |
---|---|---|---|
QIB | 859200 | 91697600 | 106.72 |
NIB | 644800 | 238539200 | 369.94 |
RETAIL | 1504000 | 208404800 | 138.57 |
Total | 3008000 | 538641600 | 179.07 |
Retail Apps | 130253 | © IPO Premium |
HNI Interest Cost per share (7 Days) | |||||
---|---|---|---|---|---|
@7% ₹39.23 | @8% ₹44.84 | @9% ₹50.44 | @10% ₹56.05 | @11% ₹61.65 | @12% ₹67.26 |
ANCHOR INVESTORS
Name of the Anchor Investor | No. of Equity Shares allocated | % of Anchor | Amount Allocated (in Crores) |
---|---|---|---|
Vikasa India EIF I Fund – Zodiac Global Opportunity Fund | 2,11,200 | 16.40% | 1.672 |
Chanakya Opportunities Fund I | 1,28,000 | 9.94% | 1.011 |
Moneywise Financial Services Pvt. Ltd | 1,28,000 | 9.94% | 1.011 |
Aries Opportunities Fund Limited | 2,52,800 | 19.63% | 1.994 |
Neomile Growth Fund – Series I | 1,90,400 | 14.78% | 1.506 |
Meru Investment Fund PCC – Cell 1 | 3,77,600 | 29.32% | 2.989 |
Established in 2000, Zenith Drugs Limited stands as a distinguished pharmaceutical enterprise, dedicated to the production and distribution of top-tier, cost-effective medications, notably generic drugs.
Operating in strict accordance with WHO-GMP standards, the company has earned recognition for its unwavering dedication to quality, exemplified by its attainment of the ISO 9001:2015 certification from a reputable EuroUK certification authority.
Zenith Drugs Limited offers a diverse product line encompassing:
- ORS Powder
- Liquid Orals
- Ointments
Zenith Drugs IPO Details
Issue Size | 5,148,800 shares (aggregating up to ₹40.68 Cr) |
Fresh Issue | 5,148,800 shares (aggregating up to ₹40.68 Cr) |
Issue Type | Book Built Issue IPO |
Listing At | NSE SME |
Share holding pre issue | 12,000,000 |
Share holding post issue | 17,148,800 |
Market Maker portion | 852,800 shares (YES 852800) Gretex Share Broking |
Zenith Drugs IPO Reservation
Investor Category | Shares Offered |
---|---|
QIB Shares Offered | Not more than 16.69% of the Net Issue |
Retail Shares Offered | Not less than 29.21% of the Net Issue |
NII (HNI) Shares Offered | Not less than 12.52% of the Net Issue |
Zenith Drugs IPO Lead Manager(s)
- Gretex Corporate Services Limited
Key Performance Indicator
KPI | 2023 | 2022 | 2021 |
---|---|---|---|
ROE | 35.13% | 29.83% | 40.73% |
ROCE | 37.29% | 30.08% | 36.52% |
D/E Ratio | 1.51 | 1.56 | 1.73 |
RONW | 29.88% | 25.96% | 33.84% |
Basic & Diluted EPS | 4.29 | 2.62 | 2.52 |
P/E Ratio | 18.4 | - | - |
P/BV Ratio | 5.5 | - | - |
Strength Factors
Experienced Promoters and Management Team: The company benefits from seasoned promoters and a skilled management team, providing strong leadership and strategic direction.
Cost Efficiency: Emphasis on cost efficiency ensures optimal resource utilization, enhancing profitability and competitiveness.
Formulation & Development: Capabilities in formulation and development enable the company to innovate and adapt to changing market needs, fostering product differentiation and growth.
Regulatory Compliance: Adherence to regulatory requirements ensures legal and operational compliance, mitigating risks and enhancing reputation.
Global Reach: The company's global reach expands market opportunities and diversified revenue streams, reducing dependency on specific regions..
Risk Factors
Restrictive Financing Conditions: The company operates under restrictive conditions imposed by lenders, necessitating prior written consent for capital structure changes, amalgamation schemes, and borrowing arrangements. This could potentially limit the company's financial flexibility and operational agility from an external viewpoint.
Dependency on Raw Materials and Suppliers: Heavy reliance on major raw materials and a select group of suppliers, without long-term agreements, poses a risk. Inability to secure adequate raw materials at competitive prices may adversely affect the company's business operations and financial health, observed from an external standpoint.
Manufacturing and Quality Control Risks: Any lapses in manufacturing or quality control processes could disrupt operations, tarnish the company's reputation for excellence, and expose it to potential legal liabilities. This could have a detrimental impact on the company's business prospects, cash flows, and financial condition from an external observer's perspective.
Increased Competition: Inadequate response to heightened competition may result in loss of market share and declining profitability. This could negatively affect the company's business performance, operational outcomes, and financial standing as viewed externally.
Delays and Defaults in Customer Payments: Delays or defaults in customer payments could strain working capital and diminish profits, impacting the company's operational efficiency and financial stability from a third-party viewpoint.
Company Financials
Zenith Drugs Limited Financial Information (Restated Consolidated)
Zenith Drugs Limited's revenue increased by 24.85% and profit after tax (PAT) rose by 64.7% between the financial year ending with March 31, 2023 and March 31, 2022.
Period | 30 Sep 2023 | Mar 2023 | Mar 2022 |
Assets | 11,249.04 | 9,793.83 | 6,858.47 |
Revenue | 6,948.43 | 11,569.65 | 9,266.63 |
Profit | 539.38 | 515.29 | 312.86 |
Net Worth | 2,264.96 | 1,724.42 | 1,209.09 |
Reserves | 1,064.96 | 1,684.42 | 1,169.09 |
Borrowing | 2,902.81 | 2,605.03 | 1,880.86 |
Amount in ₹ Lakhs |
Zenith Drugs IPO Lead Manager(s)
- Gretex Corporate Services Limited
Zenith Drug IPO Anchor List
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/ipo_status.html